The aim of this study was to determine whether in vitro induced erythromycin resistance facilitates the cross-resistance to the novel fluoroketolide, solithromycin, in Staphylococcus aureus. Four strains of methicillin-susceptible S. aureus strains S2, S3, S5 and S7 were successfully induced to establish erythromycin-resistant strains by continuous in vitro culture with erythromycin. Mutations at drug binding sites were shown to increase the minimal inhibitory concentrations for ketolides, including telithromycin and the novel compound solithromycin, but did not increase for lincosamides, chloramphenicols or oxazolidinones. In S2-, S5-and S7-derived strains, L22 protein mutations occurred first, resulting in a low level of cross-resistance to ketolides (≤4 μg/mL). The L4 protein mutations were dependent on the L22 protein, resulting in high-level cross-resistance to ketolides (≥8 μg/mL). In S3-derived strains, high levels of cross-resistance occurred concurrently in the 23S rRNA domains II/V and the L22 protein. Hence, long-term exposure of erythromycin results in resistance to ketolides in S. aureus through drug binding site mutations. These results demonstrate that since erythromycin has been used clinically for a long time, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases.
INTRODUCTION
Staphylococcus aureus is one of the most notorious pathogenic microorganisms in both nosocomial and community settings worldwide. Staphylococcus aureus causes infections of the blood, skin and soft tissues. These infections lead to the development of pneumonia, endocarditis and an array of other diseases and impose considerable economic burdens because management of them consumes manpower and materials (Shanker et al. 2017) . The treatment of S. aureus infections is now quite challenging. The misuse or heavy use of antibiotics has accelerated the development of bacterial antibiotic resistance and particularly, has leaded to the emergence of multidrug resistant S. aureus (Kaur et al. 2017) . The traditional macrolide antibiotics such as erythromycin can effectively inhibit Gram-positive bacteria including S. aureus infections. However, erythromycin could no longer be used as a first-line treatment because the resistance to erythromycin quickly arose due to the rapid dissemination of resistance genes under selective pressure (Jelić and Antolović 2016) . The two mechanistically different mechanisms through which bacteria become resistant to macrolides are targeted modification and active efflux. Methylases mediated methylation is one of the most important ways through which to modify drug binding sites. Typically, erythromycin ribosomal methylase (erm) confers multidrug resistance to macrolides, lincosamides and streptogramin B (MLSB resistance phenotype) (Strauss et al. 2016) . The active efflux of macrolides is primarily mediated by msr genes (msrA and msrB) for S. aureus, resulting in resistance to 14-and 15-membered macrolides and streptogramins B (MSB resistance phenotype) (Juda, Chudzik-Rzad and Malm 2016) .
The emergence of antibiotic resistance due to genes such as erm and msr has driven the needs for either new or improved old drugs. Ketolides are among the new emerging antibiotics used to treat infections caused by erythromycin resistant strains. For these erythromycin-based drugs, a keto group at the C-3 position of the lactone ring replaces the cladinose sugar, and a cyclic carbamate fused at the C-11 and C-12 position of the lactone ring (Krokidis et al. 2014) . Ketolides increase ribosome binding sites and enhance bacteriostatic activity against both macrolide-sensitive and -resistant bacteria (Ying and Tang 2010) . Solithromycin is a novel fluoroketolide, which exhibits stronger antibacterial activity than the older generations of macrolides and has low minimal inhibitory concentrations (MICs) of 50/90. It has broad antimicrobial activity against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Beta-hemolytic Streptococci, Legionella, Bordetella pertussis, Chlamydophila pneumoniae and S. aureus (Farrell et al. 2016; Farrell et al. 2010; Jensen, Fernandes and Unemo 2014; Hardy, Vicino and Fernandes 2016; Zhanel et al. 2016) . However, despite its potent antibacterial activity and broad antimicrobial spectrum, as well as excellent pharmacokinetic and pharmacodynamic parameters (e.g. high bioavailability for oral administration, excellent tolerability for patients with impaired liver function, intense tissue penetrability and large volume distribution (>500 L)), it has not been approved for clinical use by the Food and Drug Administration (Buege, Brown and Aitken 2017) .
Cross-resistance generally occurs in drugs that have a common binding position or structural similarity. Chemical modification of older generations of drugs is one of the most common ways to make new drugs, known as semisynthetic derivatives. Through this form of transformation, new drugs commonly qualify the basis of co-resistance. Since erythromycin, azithromycin and other old-generation macrolide drugs have been widely used for many years, the drug resistance rates are high both domestically and overseas (Choi et al. 2017; Lu et al. 2017) . Whether these drug-resistant strains are sensitive or resistant to the novel fluoroketolide, solithromycin, is not yet known. Here, an in vitro drug-resistant model was developed to assess whether S. aureus would cross-resist to solithromycin under the selective pressure of erythromycin. This investigation will provide an understanding of drug resistance mechanisms and guide appropriate drug prescription practices to constrain bacterial resistance.
METHODS

Bacterial strains
Two quality-control strains ATCC 29213 and 25923 (methicillinsusceptible S. aureus [MSSA] ) and two clinical S. aureus strains (MSSA) isolated from bloodstream and from wound secretions, respectively, were assessed. These strains were used for the in vitro drug-resistance model. The four strains were identified as S2, S3, S5 and S7 throughout the study.
Establishment of the in vitro drug-resistance model
Four independent strains with erythromycin MICs lower than 1 μg/mL were serially subcultured in erythromycin-containing Mueller-Hinton Broth (MHB). A 0.5 X MIC was used as the initial inducing concentration and then sequentially increased to 1 X, 2 X, 4 X, 8 X, 16 X, 32 X, 64 X, 128 X and 256 X MICs. Before entering the next concentration, strains at each concentration were cultured for four passages. The last-passage isolates from each concentration were cryopreserved in glycerol containing (40%) MHB at −80
• C.
MIC determination
All erythromycin-induced strains were cultured on MH agar plate for MIC determination. Three separate clones were picked up from the plate at each drug concentration and the antibiogram testing was performed by the agar dilution method following the guidelines set by the Clinical and Laboratory Standards Institute (CLSI) (Clinical and Laboratory Standards Institute 2016). The MICs of ribosomal 23S rRNA-targeted antibiotics including one macrolide agent (erythromycin), two ketolide agents (telithromycin and solithromycin), one lincosamide agent (clindamycin), one chloramphenicol agent (chloramphenicol) and one oxazolidinone agent (linezolid) were determined. The CLSI breakpoints were used for MIC interpretation.
Amplification and sequencing of drug binding sites
To elucidate the resistance mechanisms of erythromycininduced strains, the chromosomal DNA from all isolates was extracted and purified by the DNeasy Blood and Tissue Kit (QI-AGEN China Co., Shanghai, China) according to the manufacturer's protocol for Gram-positive bacteria. The six S. aureus rrn operons (including the 5S, 16S and 23S rRNA genes) as well as the genes encoding ribosomal proteins L3 (rplC), L4 (rplD) and L22 (rplV) were amplified using previously described primers (Table S1, Supporting Information) and cycling parameters (Sutcliffe et al. 1996; Locke, Hilgers and Shaw 2009) . PCR products were sequenced with their specific primers (Table S1 , Supporting Information) by the Beijing Genomics Institute (BGI, Shenzhen, China).
RESULTS
Identification of erythromycin-resistant strains and their susceptibility to other antibiotics
After the antimicrobial susceptibility test, erythromycintolerant strains with differing levels of resistance were identified and their MICs values for other antibiotics were assessed; the values are summarized in Table 1 . Erythromycin-resistant strains showed decreased susceptibility to ketolides but were sensitive to lincosamides, chloramphenicols or oxazolidinones. The trends are illustrated in Fig. 1 . The declining sensitivity to ketolides occurred early, during the fourth passage for S2-, S5-and S7-derived strains, and later, during the 16th passage for S3-derived strains.
Mutations at drug binding sites and their cross-resistance profiles
After PCR amplification and sequencing, various deletions, insertions and mutations in the ribosomal L4/L22 proteins and the 23S rRNA domains II/V were detected (see Table 2 ). In the event of a mutation at a single binding site, a slightly increased ketolides MIC was observed, for example, deletions of RFR amino acids at positions 84-86 or insertions of HITI amino acids between positions 105 and 106 in the L22 protein. In contrast, significantly increased ketolide MICs were observed in cases of combined mutations at multiple binding sites, including insertions of KW amino acids between positions 65 and 66, and G73S mutations in the L4 protein based on the L22 protein deletion mutations mentioned above for the S2-derived strains; the 23S rRNA V domain A2058G/C2207T, II domain A680G mutations and insertion of HITI amino acids between positions 105 and 106 in the L22 protein based on the V118A mutation in the L4 protein for S3-derived strains; insertion of RQGTIRA amino acids between positions 80 and 81 in the L4 protein based on the L22 protein insertion mutation mentioned above for the S5-derived strains; and mutations of G69A and T70P in the L4 protein based on the L22 protein insertion mutation mentioned above for S7-derived strains. On the other hand, L22 protein mutations decreased susceptibility to ketolides, which occurred earlier than other binding site mutations and provided a context for the emergence of high-level resistance.
DISCUSSION
Induction of drug-resistant bacteria in vitro by continuous culture is a common method for simulating long-term treatment in vivo. By using this method, an understanding of the resistance mechanisms that can provide prescriptive guidance for the management of bacterial infectious disease is obtained. In this study, S. aureus strains with differing levels of erythromycin resistance were successfully established after a long-period of drug selection. These strains do not necessarily represent isolated strains outside the laboratory and may not be dominant when competing with clinical isolates (Linkevicius, Sandegren and Andersson 2013) . However, they do provide insight into clinical mutants because similar genes are mutated in the laboratory as in the clinic, although laboratory-derived mutants differ in the position and type of mutations. For example, S. pneumoniae that exhibits reduced susceptibility or resistance to telithromycin in the laboratory may comprise deletions in A752 in domain II of 23S rRNA, C2611U mutations in domain V of 23S rRNA, A292G/C297T/T318A/A319G/C324A mutations in the in vitro drug resistance model can provide insight into clinically relevant drug-resistance mechanisms, especially for new drugs. Erythromycin has been widely used since the 1950s (Dinos 2017) . Therefore, it is meaningful to assess the susceptibility of bacteria to novel ketolides. This is accomplished through continuous culture with erythromycin to establish resistant strains in vitro. These strains were then evaluated for their susceptibility to ketolides and other 23S-rRNA targeted antibiotics. The results showed that the antibacterial activities of lincosamides, chloramphenicols and oxazolidinones were only slightly affected, as shown in their MIC distributions. However, since the MICs of these induced strains were significantly higher than those of natural strains, the susceptibility to ketolides (whether telithromycin or solithromycin) decreased. Therefore, this use of erythromycin provides a basis for analyzing resistance to its derivatives and other types of antibiotics.
In order to understand the resistance mechanisms of these erythromycin-exposed strains, mutations were primarily considered at macrolide-binding associated sites within the 23S rRAN domain II/V and within the ribosomal L3/L4/L22 proteins. There are two reasons why mutations in rRNA methylases or efflux genes were not considered. First, the S. aureus parental strains were confirmed to contain no rRNA methylases and efflux genes. Second, these genes were acquired horizontally or vertically during the macrolide pressure from previously obtained strains (Chancey, Zähner and Stephens 2012) . It is known that A2058G transition weakens the susceptibility of macrolides (e.g. erythromycin, azithromycin and telithromycin) to the clinical strains of S. aureus, S. pneumoniae, C. pneumoniae and M. genitalium (Tait-Kamradt et al. 2000a; Canu et al. 2002; Prunier et al. 2005; Jensen, Fernandes and Unemo 2014; Gomes et al. 2017) . Since A2058 and A2059 in domain V of the 23S rRNA form a crevice at the entrance to the peptide exit tunnel, the erythromycin binding at A2058 blocks the tunnel and terminates nascent peptide elongation (Canu et al. 2002) . Transition of A-G at position 2058 decreased binding affinity, which directly led to erythromycin resistance (Prunier et al. 2005) . In this study, the A2058G transition was observed, as well as C2207T and A680G transitions in domains II and V of the 23S rRNA. To the best of our knowledge, this is the first report of this relationship with macrolide resistance. It is likely that many other nucleotides in the same region (such as A752 and C2611) hamper the binding of antibiotics by changing the conformation and flexibility of nucleotides near the Peptidyl Transferase Center (PTC) (Pfister et al. 2005; Davidovich, Bashan and Yonath 2008) . Hence, the transitions in domains II and V of the 23S rRNA play a crucial role in ketolide (including solithromycin) resistance.
The ribosomal proteins L4 and L22 are constituents of the PTC region and are involved in macrolide resistance through conformational intervention (Tait-Kamradt et al. 2000b; Berisio et al. 2006) . Mutations such as G95D and A97D or amino acid insertions at position 109 of the ribosomal L22 protein can significantly increase the macrolide MICs in S. pneumoniae (Musher et al. 2002; Farrell et al. 2003) . Herein, deletion or insertion mutations in the L22 protein were close to the reported region but differed in the specific mutation type. Importantly, this study first discovered mutations in the L22 protein and provided the basis for the emergence of high-level cross-resistance. Other Tait-Kamradt et al. 2000b) . In this study, the ribosomal L4 protein mutations of strains derived from S2 and S7 were consistent with previous reports in regard to the mutated region, but differed in the specific mutation type. Previously unreported mutations in the ribosomal L4 protein were also observed in strains derived from S3 and S5. In different studies, the differences in mutations within the same protein may be related to the species examined. Taken together, mutations in the L22 and L4 proteins can play either a dominant or accessory role in the selection of macrolide-resistant isolates, depending upon the region and type of mutation. In addition, mutations in the L22 protein appear to provide a selectiveevolutionary advantage over mutations in the L4 protein.
Several limitations of the present study should be noted. First, probably, during the erythromycin induction, there may be other mutations rather than just in the L4 and L22 proteins and the 23S rRNA V domain, but we cannot capture them because ordinary PCR assay can only be applied to amplify the target genes. Second, we deduced the relationship between mutations in the present study and the solithromycin resistance mentioned in previous reports. In fact, the best method is to use CRISR/Cas9 or other tools for reverse testing to confirm the correlation.
CONCLUSIONS
A breakout of bacterial drug resistance stimulates the nextgeneration drug research and development to counteract the old drug-resistance gene barrier. Such a breakout also promotes the simultaneous evolution of resistance against new drugs. Properly prescribing antibiotics provide maximum patient benefit while avoiding drug resistance. Bacterial drug-resistance profiles and antibiotic resistance risk factors will guide the appropriate prescription of new drugs while constraining the evolution of bacterial resistance. Long-term exposure of erythromycin can provide for resistance to ketolides by S. aureus through drug binding site mutations within the 23S rRNA II/V domains and L4 and L22 proteins. Among them, mutations in the L22 protein occurs first, leading to low levels of cross-resistance and providing breakouts of high-level resistance. Therefore, these results demonstrate that since erythromycin has long been used clinically, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases. Clinical application of any drug, however, must consider more factors such as pharmacokinetic and pharmacodynamic parameters, local epidemiological situations and economic burden.
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